{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:39:56Z","timestamp":1791124796881,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1999,12,1]],"date-time":"1999-12-01T00:00:00Z","timestamp":944006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS PharmSci"],"published-print":{"date-parts":[[1999,12]]},"DOI":"10.1208\/ps010418","type":"journal-article","created":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T21:26:02Z","timestamp":1059773162000},"page":"14-19","source":"Crossref","is-referenced-by-count":54,"title":["Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P 4503A4"],"prefix":"10.1208","volume":"1","author":[{"given":"Meguru","family":"Achira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[1999,12,1]]},"reference":[{"key":"14014_CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","volume":"13","author":"VJ Wacher","year":"1995","unstructured":"Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995;13:129\u2013134.","journal-title":"Mol Carcinog"},{"key":"14014_CR2","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","volume":"338","author":"JC Kolars","year":"1991","unstructured":"Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporine by the gut. Lancet. 1991;338:1488\u20131490.","journal-title":"Lancet"},{"key":"14014_CR3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/clpt.1992.171","volume":"52","author":"MF Hebert","year":"1992","unstructured":"Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther. 1992;52:453\u2013457.","journal-title":"Clin Pharmacol Ther"},{"key":"14014_CR4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0009-9236(95)90168-X","volume":"58","author":"CY Wu","year":"1995","unstructured":"Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther. 1995;58:492\u2013497.","journal-title":"Clin Pharmacol Ther"},{"key":"14014_CR5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0009-9236(96)90162-9","volume":"60","author":"MF Paine","year":"1996","unstructured":"Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996;60:14\u201324.","journal-title":"Clin Pharmacol Ther"},{"key":"14014_CR6","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/js980082d","volume":"87","author":"VJ Wacher","year":"1998","unstructured":"Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 1998;87:1322\u20131330.","journal-title":"J Pharm Sci"},{"key":"14014_CR7","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","volume":"94","author":"A Sparrenboom","year":"1997","unstructured":"Sparrenboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen, JH, van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94:2031\u20132035.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14014_CR8","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1073\/pnas.94.8.4028","volume":"94","author":"AH Schinkel","year":"1999","unstructured":"Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJM, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JMJM, Fibbe WE, Borst P. Normal viability and altered pharmacokinetis in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA. 1999;94:4028\u20134033.","journal-title":"Proc Natl Acad Sci USA"},{"key":"14014_CR9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-9236(97)90150-8","volume":"62","author":"LC Floren","year":"1997","unstructured":"Floren LC, Bekersky I, Benet LZ, Mekki Q, Diessler D, Lee JW, Roberts JP, Hebert MF. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther. 1997;62:41\u201349.","journal-title":"Clin Pharmacol Ther"},{"key":"14014_CR10","first-page":"246","volume":"287","author":"Y Zhang","year":"1998","unstructured":"Zhang Y, Hsieh Y, Izumi T, Lin ET, Benet LZ. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther. 1998;287:246\u2013252.","journal-title":"J Pharmacol Exp Ther"},{"key":"14014_CR11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/A:1018872207437","volume":"16","author":"H Ito","year":"1999","unstructured":"Ito H, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption: theoretical approach. Pharm Res. 1999;16:225\u2013231.","journal-title":"Pharm Res"}],"container-title":["AAPS PharmSci"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/ps010418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/ps010418\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/ps010418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T03:41:55Z","timestamp":1559619715000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/ps010418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,12]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,12]]}},"alternative-id":["14014"],"URL":"https:\/\/doi.org\/10.1208\/ps010418","relation":{},"ISSN":["1522-1059"],"issn-type":[{"value":"1522-1059","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,12]]}}}